NVO News and Press, Novo Nordisk A/S From 06/13/24

2024-06-13 08:58:36 ET More on Vivani Medical Seeking Alpha’s Quant Rating on Vivani Medical Historical earnings data for Vivani Medical Financial information for Vivani Medical Read the full article on Seeking Alpha For further details see: ...

2024-06-13 02:30:42 ET Summary A difficult period for Pfizer might be coming to an end, as serious setbacks and tough Y/Y comps are in the rearview mirror. The first quarter performance of the commercial business exceeded Street expectations, and the company maintained its full-ye...

2024-06-12 12:33:43 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? ...

2024-06-12 10:16:29 ET Summary Madrigal Pharmaceuticals, Inc. stock has enjoyed peaks and troughs as it has pursued its path to the approval of NASH drug Rezdiffra. The company's stock was buoyant yesterday, enjoying a 15% gain after Wolfe Research initiated positive coverage. ...

2024-06-11 15:42:39 ET More on Corbus Pharmaceuticals Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025 Neutral On Corbus Pharmaceuticals' Financials And Clinical Progress In Oncology Corbus outlines phase 1 results from ADC trial for bladder, ce...

2024-06-11 13:25:29 ET The major market averages have shifted lower for the most part on Tuesday ahead of key inflation data and the Federal Reserve’s latest rate decision, but some stocks are still flashing signs of being overbought according to the relative strength index technical...

2024-06-11 11:52:50 ET More on Novo Nordisk Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic SA Asks: Is Eli Lilly or Novo Nord...

2024-06-11 11:25:13 ET Summary The BlackRock Enhanced International Dividend Trust offers attractive geographical diversification and a high level of income with a yield of 7.28%. The BGY closed-end fund's lower yield compared to similar funds appears to be partly due to its less ...

(NewsDirect) Compared to their non-orphan counterparts, orphan drugs have consistently outpaced growth and have become a major part of pharma’s mainstream business. The U.S. FDA's orphan drug designation, established under the Orphan Drug Act of 1983, encourages the development of trea...

2024-06-11 04:57:00 ET Shares of Structure Therapeutics (NASDAQ: GPCR) shot up more than 50% during the first week of June. The stock market is responding to a positive readout for an experimental weight-management drug the company is working on. Structure Therapeutics is a clin...